Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Protective Effect of Pediococcus pentosaceus LI05 Against Clostridium difficile Infection in a Mouse Model

  • 2018-10-09
  • Frontiers in Microbiology 9
    • Qiaomai Xu
    • Silan Gu
    • Yunbo Chen
    • Jiazheng Quan
    • L. Lv
    • Da-Zhi Chen
    • B. Zheng
    • Lichen Xu
    • Lanjuan Li

Abstract

Clostridium difficile infection (CDI) is a major cause of infectious diarrhea among hospitalized patients. Probiotics could be instrumental in restoring the intestinal dysbiosis caused by CDI. Here, we examined the protective effect of Pediococcus pentosaceus LI05 in a mouse CDI model. C57BL/6 mice were administrated P. pentosaceus LI05 (LI05 group) or sterile anaerobic PBS (CDI group) everyday for 14 days. Mice were exposed to antibiotics cocktail for 5 days; then challenged with C. difficile strain VPI10463. Mice were monitored daily for survival and weight loss. Colonic tissue and serum samples were assessed for intestinal histopathology, intestinal barrier function and systemic inflammation. The oral administration of P. pentosaceus LI05 improved the survival rate and alleviated the histopathological impact of C. difficile. Compared to the CDI group, the levels of inflammatory mediators in the colon as well as inflammatory cytokines and chemokines in serum were substantially attenuated in the LI05 group. P. pentosaceus LI05 alleviated the CDI-induced of disruption of ZO-1, occludin and claudin-1. Additionally, fecal microbiome analysis showed an enrichment in the abundance of the Porphyromonadaceae and Rikenellaceae, while, the relative abundance of Enterobacteriaceae were decreased. Our results demonstrated that the preventive effect of P. pentosaceus LI05 against CDI was mediated via improving tight junction proteins and down-regulating the inflammatory response. Therefore, P. pentosaceus LI05 could be a promising probiotic in CDI.

Keywords: Clostridium difficile; inflammatory cytokines; intestinal dysbiosis; probiotics; tight junction proteins.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Pediococcus pentosaceus MAK99P15PImproved Intestinal Barrier FunctionBeneficial
Moderate
Pediococcus pentosaceus MAK99P15PImproved Intestinal HistopathologyBeneficial
Moderate
Pediococcus pentosaceus MAK99P15PImproved Microbiota CompositionBeneficial
Moderate
Pediococcus pentosaceus MAK99P15PImproved Survival RateBeneficial
Moderate
Pediococcus pentosaceus MAK99P15PReduced Inflammatory MediatorsBeneficial
Large
Pediococcus pentosaceus PP06Improved Intestinal Barrier FunctionBeneficial
Moderate
Pediococcus pentosaceus PP06Improved Survival RateBeneficial
Moderate
Pediococcus pentosaceus PP06Reduced Inflammation LevelsBeneficial
Large
Pediococcus pentosaceus PP06Restored Gut Microbiome BalanceBeneficial
Moderate
Back to top